BioSpace News Archive

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, announced the first customer shipments of Revio long-read sequencing systems will commence on March 8, 2023.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, following the close of the U.S. financial markets.

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022.

Enanta Pharmaceuticals, Inc . today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.

Volastra Therapeutics today announced completion of the in-license of Amgen’s sovilnesib (AMG650), an oral, first-in-class small molecule inhibitor of KIF18A. In parallel, the company has closed a $60 million Series A financing.

Viridian Therapeutics, Inc. today announced that multiple abstracts on VRDN-001 and VRDN-002—the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—will be presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), to be held March 11 to 16, 2023, in Orlando, Florida.

Certara, Inc., a global leader in biosimulation, announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based modeling and simulation platform.

MBX Biosciences, Inc. today announced its participation at the virtual Oppenheimer 33rd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Tuesday, March 14, 2023 at 10:40 a.m. ET.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced its first patient enrolled in South Korea for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s president and CEO, Lisa Ricciardi will present at the annual Oppenheimer & Co Healthcare Conference taking place in a virtual format from March 13-15, 2023.